# 1A Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse2Genome-Wide Association Study and Population-Specific Optimization

- 3
- 4 Johanna L. Smith, Ph.D.\*<sup>1</sup>, Catherine Tcheandjieu, DVM, Ph.D.\*<sup>2,3,4,5</sup>, Ozan Dikilitas, M.D.<sup>1</sup>, Kruthika Iyer,
- 5 Ph.D.<sup>6</sup>, Kazuo Miyazawa, M.D., Ph.D.<sup>7</sup>, Austin Hilliard, Ph.D.<sup>4,6</sup>, Julie Lynch, Ph.D.<sup>8</sup>, Jerome I. Rotter, M.D.,
- 6 Ph.D.<sup>9</sup>, Yii-Der Ida Chen, Ph.D.<sup>9</sup>, Wayne Huey-Herng Sheu<sup>10,11,12</sup>, Kyong-Mi Chang, M.D.<sup>13</sup>, Stavroula
- 7 Kanoni, Ph.D.<sup>14</sup>, Phil Tsao, Ph.D.<sup>4,15</sup>, Kaoru Ito, M.D., Ph.D.<sup>7</sup>, Matthew Kosel, B.S.<sup>16</sup>, Shoa L. Clarke,
- 8 Ph.D.<sup>4,15</sup>, Daniel J. Schaid, Ph.D.<sup>16</sup>, Themistocles L. Assimes, Ph.D.<sup>#15</sup>, Iftikhar J. Kullo, M.D.<sup>#1</sup>
- 9
- <sup>1</sup> Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
- <sup>2</sup> Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA,
   USA.
- <sup>3</sup> Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA.
- <sup>4</sup> VA Palo Alto Health Care System, Palo Alto, CA, USA.
- <sup>5</sup> Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine,
- 16 Stanford, CA, USA.
- 17 <sup>6</sup> Stanford University School of Medicine, Palo Alto, CA, USA.
- 18 <sup>7</sup> Riken Ctr. for Integrative Medical Sciences, Yokohama City, Japan.
- <sup>8</sup> Salt Lake City VA Met CTR., Salt Lake City, UT, USA.
- <sup>9</sup> Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Lundquist
- 21 Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
- <sup>10</sup> Institute of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan.
- <sup>11</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Veterans General
- 24 Hospital, Taipei, Taiwan.
- <sup>12</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans
- 26 General Hospital, Taichung, Taiwan.
- 27 <sup>13</sup> Corporal Michael J Crescenz VA Medical Ctr. Philadelphia, PA, USA.
- 28 <sup>14</sup> Queen Mary University of London, Cambridge, UK.
- <sup>15</sup> Stanford University, Stanford, CA, USA.
- <sup>16</sup> Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
- 31
- 32 \* Co-first Authors
- 33 <sup>#</sup> Corresponding Authors
- 34
- 35 Iftikhar J. Kullo, 200 First St SW, Rochester MN, 55905, Kullo.Iftikhar@mayo.edu
- 36 Themistocles Assimes, Stanford University, Stanford, CA, USA.

### 37 Abstract (250 words)

Background: Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate
 equitable clinical use, we developed PRS for coronary heart disease (PRS<sub>CHD</sub>) for 5 genetic ancestry
 groups.

- 41 Methods: We derived ancestry-specific and multi-ancestry PRS<sub>CHD</sub> based on pruning and thresholding
- 42 (PRS<sub>P+T</sub>) and continuous shrinkage priors (PRS<sub>CSx</sub>) applied on summary statistics from the largest multi-
- 43 ancestry genome-wide meta-analysis for CHD to date, including 1.1 million participants from 5
- 44 continental populations. Following training and optimization of PRS<sub>CHD</sub> in the Million Veteran Program,
- 45 we evaluated predictive performance of the best performing PRS<sub>CHD</sub> in 176,988 individuals across 9
- 46 cohorts of diverse genetic ancestry.
- 47 **Results:** Multi-ancestry PRS<sub>P+T</sub> outperformed ancestry specific PRS<sub>P+T</sub> across a range of tuning values. In
- 48 training stage, for all ancestry groups, PRS<sub>CSx</sub> performed better than PRS<sub>P+T</sub> and multi-ancestry PRS
- 49 outperformed ancestry-specific PRS. In independent validation cohorts, the selected multi-ancestry
- 50 PRS<sub>P+T</sub> demonstrated the strongest association with CHD in individuals of South Asian (SAS) and
- 51 European (EUR) ancestry (OR per 1SD[95% CI]; 2.75[2.41-3.14], 1.65[1.59-1.72]), followed by East Asian
- 52 (EAS) (1.56[1.50-1.61]), Hispanic/Latino (HIS) (1.38[1.24-1.54]), and weakest in African (AFR) ancestry
- 53 (1.16[1.11-1.21]). The selected multi-ancestry PRS<sub>CSx</sub> showed stronger association with CHD in
- 54 comparison within each ancestry group where the association was strongest in SAS (2.67[2.38-3.00]) and
- 55 EUR (1.65[1.59-1.71]), progressively decreasing in EAS (1.59[1.54-1.64]), HIS (1.51[1.35-1.69]), and
- 56 lowest in AFR (1.20[1.15-1.26]).
- 57 **Conclusions:** Utilizing diverse summary statistics from a large multi-ancestry genome-wide meta-analysis
- 58 led to improved performance of PRS<sub>CHD</sub> in most ancestry groups compared to single-ancestry methods.
- 59 Improvement of predictive performance was limited, specifically in AFR and HIS, despite use of one of
- 60 the largest and most diverse set of training and validation cohorts to date. This highlights the need for
- 61 larger GWAS datasets of AFR and HIS individuals to enhance performance of PRS<sub>CHD</sub>.

# 62 Introduction

63 Coronary heart disease (CHD) is a leading cause of death in the United States (U.S.) and 64 worldwide <sup>1</sup>. CHD has an estimated heritability of 40-60% and the majority of the heritable risk is 65 attributable to a polygenic component, i.e., the aggregation of modest effects across many genetic variants<sup>2</sup>. Polygenic risk scores (PRS) capture a proportion of that heritability and are typically 66 67 constructed by summing the products of the effect-size and the number of risk alleles at associated loci <sup>3,4</sup>. PRS for CHD have evolved over the last decade as progressively larger genome wide association 68 studies (GWAS) have been reported <sup>5-8</sup>. These PRS have been evaluated in several studies and are 69 associated with incident CHD independent of conventional risk factors such as hypertension, 70 71 hypercholesterolemia, diabetes, and smoking as well as family history of CHD<sup>8-10</sup>.

72 Most PRS for CHD have been developed, optimized, and validated in cohorts consisting largely of 73 individuals of European (EUR) ancestry (here and throughout the manuscript 'ancestry' refers to genetic ancestry)<sup>11-14</sup>. Furthermore, the portability of these PRS to non-EUR groups is impacted by differences in 74 75 allele frequencies (AF), effect sizes, and linkage disequilibrium (LD) patterns across ancestry groups, 76 typically resulting in reduced predictive performance as studied populations diverge in these factors; an observation most notable between EUR and African (AFR) ancestry populations <sup>6,11,15</sup>. We previously 77 observed significantly lower performance of several EUR-derived PRS for CHD in AFR ancestry individuals 78 79 <sup>16,17</sup>. To prevent exacerbation of health disparities in the context of genomic medicine, there is a need to improve performance of PRS for CHD for non-EUR populations. 80

81 In this study, we leveraged a large scale, ancestrally diverse genome-wide meta-analysis for CHD 82 to construct PRS for CHD optimized for EUR, AFR, Hispanic/Latino (HIS), East Asian (EAS), and South Asian 83 (SAS) ancestries. To this end, we utilized two PRS derivation methods, pruning and thresholding (P+T) and the continuous shrinkage prior based PRS-CSx<sup>8,18</sup>. We assessed the performance of the multi-84 85 ancestry PRS in individuals with diverse ancestry belonging to 8 independent validation cohorts. Finally, a 86 PRS was selected for clinical implementation in the electronic Medical Records and Genomics (eMERGE) 87 network phase IV study in which PRS-informed risk profiles for several common conditions are being 88 returned to participants <sup>19</sup>.

89

# 90 Methods

# 91 GWAS Summary Statistics for PRS Development

We developed PRS using both ancestry-specific and multi-ancestry meta-analysis summary
statistics from a large-scale multi-ancestry GWAS for CHD including 1.1 million diverse participants with
243,392 CHD cases <sup>17</sup>. This diverse meta-analysis included 17,202 AFR, 6,378 HIS, 29,319 EAS, and
190,776 EUR individuals with CHD belonging to four cohorts including the Million Veteran Program
(MVP), the UK Biobank (UKBB), CARDIOGRAMplusC4D Consortium (2015 release), and Biobank Japan
(BBJ) (Figure 1) <sup>17,20-22</sup>.

We used two distinct methods to construct PRS, namely, pruning and thresholding (P+T) and the
 continuous shrinkage prior based PRS-CSx <sup>8,18</sup>. Ancestry-specific PRS were defined from ancestry-specific

100 GWAS summary statistics (i.e., EUR specific summary statistics were used to develop a EUR specific PRS),

- and multi-ancestry PRS were defined as PRS derived from multi-ancestry summary statistics. These PRS
- were then trained and optimized in a separate set of individuals from the MVP and externally validated
- 103 in several diverse cohorts including the Atherosclerosis Risk in Communities (ARIC)<sup>23</sup>, Multi-Ethnic Study
- 104 of Atherosclerosis (MESA)<sup>24</sup>, Cardiovascular Health Study (CHS)<sup>25</sup>, Women's Health Initiative (WHI)<sup>26</sup>,
- 105 eMERGE Phases I-III genotyped cohort <sup>27</sup>, Biobank Japan (BBJ) <sup>28</sup>, Osaka Acute Coronary Insufficiency
- 106 (OACIS) study <sup>29</sup>, the TAICHI Consortium <sup>30</sup>, and individuals of SAS ancestry from the UKBB <sup>31</sup> (Table S1;
- 107 Supplemental File 1).

### 108 **Pruning and Thresholding (P+T)**

- 109 We derived two independent sets of PRS (ancestry-specific and multi-ancestry PRS) in two sequential
- steps: First, we excluded from the base GWAS summary statistics, correlated single nucleotide variants
- (SNVs) by LD pruning, applying 4 different  $R^2$  thresholding values (0.2, 0.5, 0.8, and 0.9) and 2 different
- window distances (250kb and 500kb) within which these  $R^2$  were applied. LD pruning for ancestry-
- specific PRS was performed based on reference panels comprised of 4,000 participants from each
- respective ancestry (EUR, AFR, HIS, and ASN), selected among MVP participants included in the large-
- scale GWAS for CHD. The LD pruning for the multi-ancestry PRS was performed on the full subset of
- 116 16,000 individuals from EUR, AFR, HIS, and ASN as the reference panel. This step generated 8 ancestry-
- specific summary statistics and 8 multi-ancestry summary statistics for PRS development. Second, for
- each newly generated summary statistic from step 1, we applied 16 different p-value thresholds (5×10<sup>-08</sup>,
- 119 1×10<sup>-04</sup>, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1) (Figure S1; Supplemental
- 120 File 1). These led to 128 summary statistics within each ancestry, which were used to train the ancestry-
- specific PRS. Similarly, we obtained 128 multi-ancestry-based summary statistics to train the multi-
- 122 ancestry PRS (PRS<sub>P+T</sub>).

# 123 Continuous shrinkage (PRS-CSx)

- 124 We applied a continuous shrinkage method, PRS-CSx (PRS<sub>CSx</sub>), on the effect sizes of a subset of 1.4 million
- well curated HapMap SNVs on each ancestry-specific summary statistic. To identify the optimal shrinkage
- parameter, we applied 4 different global shrinkage phi parameters  $(1, 1e^{-02}, 1e^{-04}, \text{ and } 1e^{-06})$ . LD
- reference panels used were EUR, AFR, AMR and EAS from the 1000 Genomes project. The multi-ancestry
- 128 PRS were constructed from the meta-analysis of ancestry-specific summary statistics obtained after
- applying the global shrinkage phi. For each ancestry, 4 ancestry-specific newly derived summary statistics
   were obtained to train ancestry-specific PRS and 4 newly derived multi-ancestry summary statistics were
- were obtained to train ancestry-specific PRS and 4 newly derived multi-ancestry summary statistics were obtained for train the multi-ancestry PRS (Figure S2; Supplemental File 1). A total of 12 ancestry-specific
- 132 PRS (one for each global shrinkage parameter value used for each ancestry group and 4 multi-ancestry
- 133 PRS) were chosen for further development (Figure S3; Supplemental File 1).

# 134 PRS Training

- 135 Following the construction of the ancestry-specific and multi-ancestry PRS<sub>P+T</sub> and PRS<sub>CSx</sub> across a range of
- training specifications, we proceeded to assess their performance in an independent set of prevalent
- 137 cases and controls from the MVP (Figure 1B, PRS Training) using multivariable logistic regression with
- 138 adjustment for age at CHD event for cases and age at the last visit in the electronic health record (EHR)
- 139 for controls, year of birth, sex, and the first 5 principal components (PCs). We compared parameter

- 140 training on the multi-ancestry reference panel set versus population-specific reference panel. Ancestry-
- specific PRS were evaluated in the corresponding ancestry, whereas the multi-ancestry PRS were
- evaluated in each ancestry. PRS with the highest observed odds ratio (OR) for CHD per 1 standard
- 143 deviation (SD) increase were deemed to have the optimal training parameter values across ancestry
- 144 populations and subsequently advanced for validation.

### 145 PRS Validation in the Million Veteran Program and Additional External Cohorts

- 146 Ancestry-specific and multi-ancestry PRS<sub>P+T</sub> and PRS<sub>CSx</sub> trained for each genetic ancestry group were
- validated in an independent cohort from the MVP and several additional diverse cohorts (Figure 1C,
- 148 Diverse Cohorts for PRS Validation). The MVP validation cohort was restricted to incident cases of CHD
- occurring after enrollment, and random controls, in a ratio of 1:10 (Figure 1C) as previously described
- <sup>17</sup>. Four prospective cohorts, namely ARIC, MESA, CHS, WHI, a subset of the UKBB comprised of
- individuals of SAS ancestry, and additionally eMERGE Phases I-III, contributed CHD incident cases and
- 152 controls of EUR, AFR, HIS, and SAS ancestry for PRS validation. Validation for EAS ancestry included
- 153 individuals from multiple case-control studies, namely Han Chinese participants from Taiwan as a part of
- the TAICHI consortium, as well as Japanese participants from the BBJ and OACIS studies who were not
- 155 part of the multi-ancestry discovery GWAS <sup>30</sup>.

Within MVP, we used diagnosis and procedure codes to identify individuals with any clinical manifestation of CHD as previously described (Supplemental File 1) <sup>17</sup>. This definition included both 'hard' (e.g., myocardial infarction, revascularization) and 'soft' outcomes (e.g., angina, non-invasive study positive for ischemia). In the 4 external validation NHLBI cohorts and the eMERGE cohort, cases were restricted to myocardial infarction and revascularization. Prevalent cases were defined as all other cases

- 161 meeting diagnosis/procedure code criteria at the time of enrollment. Additional study details are
- included in Supplemental File 1.

We calculated OR per 1-SD increase in PRS using multivariable logistic regression across all 163 164 validation cohorts. The dbGaP, eMERGE, and UKBB cohorts were adjusted for genetic ancestry using a continuous correction further defined in the Supplemental File 1 (Figure S4). The two EAS case-control 165 studies were meta-analyzed using a fixed effect inverse-variance weighted model <sup>32</sup>. For all external 166 validation cohorts, we additionally estimated OR for CHD for participants in the top 5% of PRS 167 168 distribution compared to the rest, as well as area under the curve (AUC) discrimination statistic. 169 Calibration was also assessed using the calibration function in the rms package in R to assess portability 170 to cohorts that were not available for meta-analysis (i.e., the non-EAS cohorts) (Figure S5, Supplemental File 2) <sup>33,34</sup>. 171

# 172 **Results**

# 173 PRS Training

### 174 Pruning and Thresholding (P+T)

175 Performance of the ancestry-specific and multi-ancestry  $PRS_{P+T}$  in each population is shown in Figure 2.

176 The multi-ancestry PRS<sub>P+T</sub> systematically outperformed ancestry-specific PRS<sub>P+T</sub> with noticeably higher OR

177 per SD except for the HIS ancestry group where the performance was similar (Figure 2, Supplemental

178 Figure S2). The multi-ancestry PRS<sub>P+T</sub>, performed best in HIS population, followed by the ASN population

- (1.78 and 1.73 OR per SD, respectively) (Supplemental File 2). Prediction performance of the PRS<sub>P+T</sub> for 179
- each ancestry was optimal at different p-value thresholds (Figure 2, Supplemental Figure S2). The multi-180
- ancestry PRS<sub>P+T</sub> performed best at  $R^2 \leq 0.8$  with LD blocks of 250 kb, p-value threshold of 0.01 for AFR, 181
- 182 0.03 for EUR, and 0.30 for HIS. However, the differences between these PRS and the PRS optimized at
- $R^2 \leq 0.8$  and a p-value = 0.01 were marginal, and the multi-ancestry PRS with a p-value threshold of 183
- 0.01 was chosen for validation in additional external cohorts. 184

#### 185 Continuous shrinkage (PRS-CSx)

- 186 The performances of the 12 ancestry-specific PRS<sub>C5x</sub> and 3 multi-ancestry PRS<sub>C5x</sub> built using EUR, AFR,
- HIS, and EAS summary statistics at various global shrinkage phi values for tuning  $(1e^{-02}, 1e^{-04}, and$ 187
- $1e^{-06}$ ) are shown in Figure 2. For all ancestry groups,  $phi = 1e^{-02}$  resulted in the best predictive 188
- performance for PRS<sub>CSx</sub> and the multi-ancestry PRS outperformed ancestry-specific PRS at this phi value. 189
- 190 For the EUR population, both the EUR-derived PRS and the multi-ancestry PRS performed similarly, but
- ASN and HIS populations performed best with the EUR-derived PRS, while the AFR population performed 191
- 192 best with the multi-ancestry PRS (Figure 2, Supplemental File 2). Overall, the multi-ancestry PRS<sub>CSx</sub> for the
- 193 ASN population resulted in the highest OR per/SD increase followed by EUR and HIS populations where
- 194 the strength of association was similar, and lowest in the AFR ancestry.
- 195

#### 196 **PRS Validation**

#### 197 **Million Veteran Program**

- 198 Ancestry specific PRS<sub>P+T</sub> predictive performance (OR per 1 -SD increase) for EUR (1.52), AFR (1.19), and
- HIS (1.81) was compared to the ancestry-specific PRS<sub>Csx</sub> performance for EUR (1.66), AFR (1.15), HIS 199
- 200 (1.42), and ASN (1.32) (Figure 2; Supplemental File 2). This was also compared to the multi-ancestry-
- 201 based methods using the same PRS training, i.e., the multi-ancestry PRS<sub>P+T</sub> for EUR (1.57), AFR (1.22), HIS
- 202 (1.78), and ASN (1.73), as well as PRS<sub>Csx</sub> for EUR (1.98), AFR (1.23), HIS (1.94), and ASN (2.06) (Figure 2;
- 203 Supplemental File 2). Of all the methods assessed at this step, the best performing methods tended to
- 204 be the multi-ancestry PRS<sub>CSx</sub> and multi-ancestry PRS<sub>P+T</sub>. However, there were overlapping confidence 205 intervals (CIs) with some single ancestry methods and the single-ancestry PRS<sub>cSx</sub> for EUR performed well
- 206 in other ancestries, so we decided to further assess the three methods (Figure 2).
- 207 We advanced the ancestry optimized PRS<sub>P+T</sub> and PRS<sub>CSx</sub>, for validation in an independent set of 208 incident cases and matching controls in ancestry groups of EUR, AFR, HIS, EAS, and SAS individuals. Predictive performances of the multi-ancestry PRS were assessed within each ancestry group in 209
- reference to a previously reported genome-wide PRS (i.e., PRS<sub>metaGRS</sub><sup>10</sup>) constructed using a cohort of
- 210
- predominantly of EUR ancestry (Figure 3) <sup>17</sup>. In this independent validation cohort, the multi-ancestry 211 PRS<sub>P+T</sub> and PRS<sub>CSx</sub> had a higher predictive performance compared to metaGRS (Figure 3). The multi-
- 212 213 ancestry PRS<sub>CSx</sub> had a relative increase in the estimated OR per 1-SD of 12% and 23% in reference to
- $PRS_{P+T}$  and  $PRS_{metaGRS}$ , respectively, averaged across all three genetic ancestries. 214
- 215

#### 216 Additional External Validation Cohorts

217 The best performing PRS<sub>P+T</sub> were further validated in several additional cohort and case-control studies

- of CHD including EUR, AFR, HIS, EAS, and SAS participants (Table 1). ORs for ancestry-specific and multi-
- 219 ancestry PRS<sub>P+T</sub> ranged from 1.16 in AFR to 2.75 in SAS and were comparable to published reports,
- despite inclusion of the diverse meta-analysis of GWAS (Supplemental File 2) <sup>6,17,35,36</sup>. All populations had
- 221 OR estimates for the top 5% vs the rest of the population  $\ge$  2.16 for PRS<sub>P+T</sub> except for AFR (1.68).

The two best performing  $PRS_{CSx}$  in the training dataset, a EUR-tuned PRS and a multi-ancestry PRS, both with a tuning global phi value of  $1e^{-02}$ , demonstrated similar performances in our validation

- cohorts (Table 1, Table S2; Supplemental File 1) as the multi-ancestry PRS marginally outperformed the
- EUR-tuned PRS in all but the AFR and HIS cohorts. Point estimates of the OR for subjects in the top 5<sup>th</sup> percentile of scores compared to the remaining participants shifted trend compared to those observed
- for the ORs per 1-SD for AFR, HIS, and SAS populations, but these differences were in the context of
- mostly overlapping 95% confidence intervals. When comparing the multi-ancestry  $PRS_{P+T}$  to  $PRS_{CSx}$ , the
- point estimates of ORs were similar but higher for the multi-ancestry PRS<sub>CSx</sub> for EUR, AFR, HIS, and EAS
- 230 populations. The OR per 1-SD was lower for the multi-ancestry PRS<sub>csx</sub> for the SAS population (Table 1).
- 231

# 232 **Discussion**

233 Using summary statistics from the largest multi-ancestry GWAS meta-analysis for CHD to date and 9

234 independent validations cohorts, cumulatively comprised of 1.1 million diverse participants including

nearly a quarter of a million CHD cases of EUR, AFR, HIS, EAS, and SAS descent <sup>17</sup>, we developed, trained,

and validated multi-ancestry and ancestry-specific PRS models to address the gap in predictive

237 performance that currently exists between EUR and non-EUR ancestries.

238 We observed that the use of summary statistics from a multi-ancestry GWAS meta-analysis, in 239 comparison to the use of ancestry-specific summary statistics, improved PRS performance in majority of 240 the ancestry groups. PRS that leveraged shared information between ancestries to estimate SNV weights 241 (i.e., PRS<sub>Csx</sub>) modestly outperformed the P+T method (i.e., PRS<sub>P+T</sub>). Based on the multi-ancestry informed PRS<sub>CSx</sub>, individuals in the high-genetic risk group (i.e., top 5% of the PRS distribution) compared to the 242 remaining participants in the respective ancestry group (EUR, AFR, HIS, EAS, and SAS), had 2.5-fold, 1.7-243 244 fold, 2.5-fold, 2.3-fold, and 5-fold increased risk of CHD, respectively. These results collectively highlight 245 complementary effects of integrating summary statistics from multiple ancestries and the use of PRS 246 derivation methods that leverage shared information and LD diversity between ancestry groups to 247 improve polygenic risk prediction for CHD.

248 Although remarkable progress has been achieved to date in both genomic discovery and polygenic risk prediction among EUR cohorts <sup>5,7-10,37-39</sup>, similar progress has not occurred among non-EUR 249 populations due to their underrepresentation in genomic studies <sup>11-14</sup>. In recent years, the number of 250 251 large-scale multi-ancestry GWAS and polygenic risk prediction studies have increased with the 252 establishment of ancestrally diverse biobanks and collaborations efforts <sup>17,18,30,40-43</sup>. Several multiancestry genomic studies, including for glycemic, hematologic and lipid traits as well as disease 253 254 phenotypes such as type 2 diabetes and CHD, have increased the number of discovered loci, and 255 improved fine-mapping and cross-population polygenic risk prediction with inclusion of non-EUR

participants <sup>17,40-42,44</sup>. Our findings are consistent with these results in that integration of summary
 statistics from several distinct ancestry groups improved predictive performance of PRS for all ancestries,
 including EUR descent. One possible explanation for these observations is identification of potential
 causal variants that are more likely to be shared between ancestries but are obscured by population specific LD patterns <sup>14,45</sup>. Another likely contributing factor to improved PRS performance is reduced
 noise in SNV effect size estimates resulting from both weighted average of population-level estimates

and increased total sample size  $^{46,47}$ .

263 Despite the use of the largest ancestrally diverse cohort available to date, the improvement in 264 the predictive performance of PRS<sub>CHD</sub> was limited in individuals of AFR ancestry compared to other ancestry groups. Prior reports investigating portability of PRS between populations noted that prediction 265 performance across a range of traits and phenotypes <sup>6,11,15,16,48,49</sup> decayed with increasing genetic 266 distance between study cohorts. Among the continental ancestry groups included in this study, AFR is 267 268 the most genetically distant population from EUR and hence the modest increase in prediction 269 performance with a multi-ancestry PRS<sub>CHD</sub> compared to the ancestry-specific counterpart. A recent 270 report showed similar heritability for CHD in the major continental ancestry groups but absence of two 271 common haplotypes at the 9p21 locus in AFR individuals, which corresponds to the largest effect locus in EUR ancestry individuals <sup>17</sup>. These findings suggest potentially a larger role of ancestry-specific causal 272 273 variants in individuals of African origin with regards to heritability for CHD.

274 Although the strength of association of PRS with CHD varied between ancestry groups, it is 275 important to consider epidemiological differences in CHD risk across these populations. In clinical 276 practice, primary prevention guidelines for CHD use absolute risk estimates for clinical decision making, such as 10-year or lifetime risk of a CHD event <sup>50</sup>. Individuals are typically classified into different risk 277 278 groups (e.g., low, borderline, intermediate, high risk) with a correlating intensity of pursued preventive 279 measures. In the United States, African American and South Asian populations have substantially higher 280 atherosclerotic cardiovascular disease (ASCVD) related mortality rates compared to non-Hispanic whites <sup>1,51</sup>. Therefore, in a future risk model for ASCVD similar to the pooled cohort equation <sup>52</sup>, incorporation of 281 282 a PRS for CHD with a narrower risk gradient in African Americans, compared to a much wider gradient in 283 non-Hispanic whites, could have more impact on re-classification into a higher risk group as we have 284 previously shown <sup>6</sup>.

Implementation of PRS in the clinical setting has begun for CHD, including at Mayo Clinic, where 285 a PRS for CHD is available in the clinical setting, based on the results of the MIGENES clinical trial <sup>53</sup>. The 286 287 eMERGE Network, in its phase IV study is returning risk assessments to participants for 11 common conditions, including CHD <sup>19</sup>. The multi-ancestry PRS<sub>P+T</sub> for CHD validated in this study <sup>19</sup> will be returned 288 289 to eMERGE participants. One of the major challenges in the clinical use of PRS include variable performance between genetic ancestry populations <sup>11,15</sup>. Developing robust PRS for diverse ancestry 290 groups is crucial to avoid worsening existing health disparities <sup>11</sup> and a National Institute of Health (NIH) 291 funded initiative is addressing this as a priority <sup>54</sup>. The active recruitment and inclusion of diverse 292 participants and continued development of novel PRS methods that target improvement of cross-293 294 population prediction using a variety of approaches (e.g., incorporation of local ancestry <sup>55</sup>, weighting by trans-ancestry genetic correlation <sup>56</sup>, and informing by fine-mapping and functional annotation <sup>57,58</sup>) will 295

be necessary for equitable implementation of PRS. Consequently, we anticipate that PRS for CHD willcontinue to evolve and improve over time.

298

### 299 Study Limitations

Despite the large and diverse composition of our study, the external validation for the SAS ancestry was
 limited to a single cohort with a modest number of cases, reducing the precision of the associated risk
 estimates. We were not able to include smoking status or family history in the models as the data was
 not available for all cohorts, and this may have affected the strength of the association of PRS with CHD
 in our analyses.

305

# 306 Conclusions

307 We demonstrated that incorporation of summary statistics from diverse genetic ancestry groups, as

308 opposed to individual ancestry groups alone, and leveraging shared information between these

309 populations, led to improved performance of PRS<sub>CHD</sub> in majority of the ancestry groups. Despite

310 utilization of one of the largest and most ancestrally diverse set of training and validation cohorts to

date, the gain in predictive performance for AFR was limited. Ongoing work is needed to narrow the

- 312 persistent performance gap for AFR ancestry individuals. Increasing AFR representation at each stage of
- 313 PRS development is necessary to lessen performance disparities, and such efforts should be a priority for
- 314 the community of genomics researchers.
- 315

# 316 Acknowledgements

317 We acknowledge the investigators and participants of the electronic Medical Records and Genomics

318 (eMERGE) Network. Infrastructure for the CHARGE Consortium is supported in part by the National

Heart, Lung, and Blood Institute (NHLBI) grant R01HL105756. This work was also supported in part by

320 the National Institutes of Health, National Heart, Lung, Long and Blood Institute (NHLBI) contract 1801UL151855 R01UL146860 and the National Institute of Diabetes and Dispetitive and Kidney Dispesse

321 1R01HL151855, R01HL146860, and the National Institute of Diabetes and Digestive and Kidney Diseases

322 contract UM1DK078616.

323

# 324 Sources of Funding

325 This work was supported by grants from the Polygenic Risk Methods in Diverse Populations (PRIMED)

326 Consortium through the National Human Genome Research Institute (NHGRI): grant U01 HG11710, the

electronic Medical Records and Genomics (eMERGE) Network funded by the NHGRI: grant U01

HG06379, a National Heart, Lung, and Blood: grant K24 HL137010, the Clinical Genome Resource

329 (ClinGEN) funded by the NHGRI: grant HG09650, and R35 GM140487.

330

# 331 **Disclosures**

- 332 **Conflict of Interest.** The authors declare that they have no conflict of interest.
- 333 Human and Animal Rights and Informed Consent. This article used data from previously published
- human studies.

# 335 **References**

- 3361.Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ,337Boehme AK, Buxton AE, et al. Heart Disease and Stroke Statistics—2023 Update: A Report From
- the American Heart Association. *Circulation*. 2023;147. doi: 10.1161/cir.00000000001123
- Kullo IJ, Ding K. Mechanisms of Disease: the genetic basis of coronary heart disease. *Nature Clinical Practice Cardiovascular Medicine*. 2007;4:558-569. doi: 10.1038/ncpcardio0982
- 341 3. Euesden J, Lewis CM, O'Reilly PF. PRSice: Polygenic Risk Score software. *Bioinformatics*.
- 342 2015;31:1466-1468. doi: https://doi.org/10.1093/bioinformatics/btu848
- 3434.Kullo IJ, Lewis CM, Inouye M, Martin AR, Ripatti S, Chatterjee N. Polygenic scores in biomedical344research. Nature Reviews Genetics. 2022. doi: 10.1038/s41576-022-00470-z
- Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic Risk Prediction and a 2-Stage
  Risk Screening Strategy for Coronary Heart Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2013;33:2261-2266. doi: 10.1161/atvbaha.112.301120
- Dikilitas O, Schaid DJ, Tcheandjieu C, Clarke SL, Assimes TL, Kullo IJ. Use of Polygenic Risk Scores
   for Coronary Heart Disease in Ancestrally Diverse Populations. *Current Cardiology Reports*.
   2022;24:1169-1177. doi: 10.1007/s11886-022-01734-0
- 7. O'Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, O'Donnell CJ,
   Willer CJ, Natarajan P. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement
   From the American Heart Association. *Circulation*. 2022;146. doi:
   10.1161/cir.00000000001077
- Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA,
   Ellinor PT, et al. Genome-wide polygenic scores for common diseases identify individuals with
   risk equivalent to monogenic mutations. *Nature Genetics*. 2018;50:1219-1224. doi:
   10.1038/s41588-018-0183-z
- Rapatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola
   M, Jula A, Sinisalo J, et al. A multilocus genetic risk score for coronary heart disease: case-control
   and prospective cohort analyses. *The Lancet*. 2010;376:1393-1400.
- Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, Lai FY, Kaptoge S,
  Brozynska M, Wang T, et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000
  Adults: Implications for Primary Prevention. J American Coll Cardiol. 2018;72:1883-1893.
- Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic
  risk scores may exacerbate health disparities. *Nature Genetics*. 2019;51:584-591. doi:
  10.1038/s41588-019-0379-x
- Manolio TA. Using the Data We Have: Improving Diversity in Genomic Research. *The American Journal of Human Genetics*. 2019;105:233-236. doi: 10.1016/j.ajhg.2019.07.008
- Clarke SL, Assimes TL, Tcheandjieu C. The Propagation of Racial Disparities in Cardiovascular
   Genomics Research. *Circulation: Genomic and Precision Medicine*. 2021;14. doi:
   10.1161/circgen.121.003178
- 37314.Gurdasani D, Barroso I, Zeggini E, Sandhu MS. Genomics of disease risk in globally diverse374populations. Nature Reviews Genetics. 2019;20:520-535. doi: 10.1038/s41576-019-0144-0
- 375 15. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, Daly MJ, Bustamante CD,
  376 Kenny EE. Human Demographic History Impacts Genetic Risk Prediction across Diverse
  377 Populations. *The American Journal of Human Genetics*. 2017;100:635-649. doi:
- 378 10.1016/j.ajhg.2017.03.004

Dikilitas O, Schaid DJ, Kosel ML, Carroll RJ, Chute CG, Denny JC, Fedotov A, Feng Q, Hakonarson
 H, Jarvik GP, et al. Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three
 Major Racial and Ethnic Groups. *The American Journal of Human Genetics*. 2020;106:707-716.
 doi: 10.1016/j.ajhg.2020.04.002

- Tcheandjieu C, Zhu X, Hilliard AT, Clarke SL, Napolioni V, Ma S, Lee KM, Fang H, Chen F, Lu Y, et al.
   Large-scale genome-wide association study of coronary artery disease in genetically diverse
   populations. *Nature Medicine*. 2022;28:1679-1692. doi: 10.1038/s41591-022-01891-3
- 386 18. Ge T, Irvin MR, Patki A, Srinivasasainagendra V, Lin Y-F, Tiwari HK, Armstrong ND, Benoit B, Chen
   387 C-Y, Choi KW, et al. Development and validation of a trans-ancestry polygenic risk score for type 2
   388 diabetes in diverse populations. *Genome Medicine*. 2022;14. doi: 10.1186/s13073-022-01074-2
- Linder J, Allworth A, Bland ST, Caraballo PJ, Chisholm R, Clayton EW, Crosslin D, Dikilitas O,
   DiVietro A, Esplin ED, et al. Returning integrated genomic risk and clinical recommendations: the
   eMERGE study. *Genetics in Medicine*. 2023. doi: https://doi.org/10.1016/j.gim.2023.100006
   Van Der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on
- the Genetic Architecture of Coronary Artery Disease. *Circulation Research*. 2018;122:433-443.
   doi: 10.1161/circresaha.117.312086
- Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low
   S-K, Okada Y, et al. Large-scale genome-wide association study in a Japanese population
   identifies novel susceptibility loci across different diseases. *Nature Genetics*. 2020;52:669-679.
   doi: 10.1038/s41588-020-0640-3
- Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP,
  Hopewell JC, et al. A comprehensive 1000 Genomes–based genome-wide association metaanalysis of coronary artery disease. *Nature Genetics*. 2015;47:1121-1130. doi: 10.1038/ng.3396
- 402 23. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. *American Journal of Epidemiology*. 1989;129:687-702.
- 404 24. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, R. JD, Kronmal
  405 R, Liu K, et al. Multi-Ethnic Study of Atherosclerosis: Objectives and Design. *American Journal of*406 *Epidemiology*. 2002;156:871-881. doi: https://doi.org/10.1093/aje/kwf113
- 407 25. (CHS) MftCHSRG, Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH,
  408 Manolio TA, Mittelmark MB, et al. The cardiovascular health study: Design and rationale. *Annals*409 *of Epidemiology*. 1991;1:263-276. doi: https://doi.org/10.1016/1047-2797(91)90005-W
- 41026.Group TWsHIS. Design of the Women's Health Initiative Clinical Trial and Observational Study.411Controlled Clinical Trials. 1998;19:61-109. doi: https://doi.org/10.1016/S0197-2456(97)00078-0
- Stanaway IB, Hall TO, Rosenthal EA, Palmer M, Naranbhai V, Knevel R, Namjou-Kahles B, Carroll
  RJ, Kiryluk K, Gordon AS, et al. The eMERGE genotype set of 83,717 subjects imputed to
  ~40 million variants genome wide and association with the herpes zoster medical record
  phenotype. *Genetic Epidemiology*. 2019;43:63-81. doi: 10.1002/gepi.22167
- Ali 28. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T, Tamakoshi A,
  Yamagata Z, Mushiroda T, et al. Overview of the Biobank Japan Project: Study design and profile.
  Journal of Epidemiology. 2017;27:S2-S8. doi: 10.1016/j.je.2016.12.005
- 419 29. Kurotobi T, Sato H, Kinjo K, Nakatani D, Mizuno H, Shimizu M, Imai K, Hori M, Group O. Reduced
  420 Collateral Circulation to the Infarct-Related Artery in Elderly Patients with Acute Myocardial
  421 Infarction. *J American Coll Cardiol*. 2004;44:28-34. doi: doi:10.1016/j.jacc.2003.11.066
- Assimes TL, Lee IT, Juang J-M, Guo X, Wang T-D, Kim ET, Lee W-J, Absher D, Chiu Y-F, Hsu C-C, et
  al. Genetics of Coronary Artery Disease in Taiwan: A Cardiometabochip Study by the Taichi
  Consortium. *PLOS ONE*. 2016;11:e0138014. doi: 10.1371/journal.pone.0138014

425 31. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray 426 M, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of 427 Complex Diseases of Middle and Old Age. PLOS Medicine. 2015;12:e1001779. doi: 428 10.1371/journal.pmed.1001779 429 32. Evangelou E, Ioannidis JPA. Meta-analysis methods for genome-wide association studies and 430 beyond. Nature Reviews Genetics. 2013;14:379-389. doi: 10.1038/nrg3472 431 Harrell Jr. FE. rms: Regression Modeling Strategies. R package version 6.3-0. 2022. 33. 432 34. Van Calster B, McLernon DJ, Van Smeden M, Wynants L, Steyerberg EW. Calibration: the Achilles 433 heel of predictive analytics. BMC Medicine. 2019;17. doi: 10.1186/s12916-019-1466-7 434 35. Mars N, Kerminen S, Feng Y-CA, Kanai M, Lall K, Thomas LF, Skogholt AH, dellaBriotta Parolo P, 435 Project TBJ, FinnGen, et al. Genome-wide risk prediction of common diseases across ancestries 436 in one million people. Cell Genomics. 2022;2. 437 36. Wang M, Menon R, MSanghamitra M, Patel AP, Chaffin M, Tanneeru D, Deshmukh M, Matthew 438 O, Apte S, Devanboo CS, et al. Validation of a Genome-Wide Polygenic Score for Coronary Artery 439 Disease in South Asians. Journal of the American College of Cardiology. 2020;76:703-714. doi: 440 https://doi.org/10.1016/j.jacc.2020.06.024 37. 441 Tada H, Melander O, Louie JZ, Catanese JJ, Rowland CM, Devlin JJ, Kathiresan S, Shiffman D. Risk 442 prediction by genetic risk scores for coronary heart disease is independent of self-reported 443 family history. European Heart Journal. 2016;37:561-567. doi: 10.1093/eurheartj/ehv462 444 38. Ding K, Bailey KR, Kullo IJ. Genotype-informed estimation of risk of coronary heart disease based 445 on genome-wide association data linked to the electronic medical record. BMC Cardiovascular 446 Disorders. 2011;11:66. doi: 10.1186/1471-2261-11-66 447 Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, Tikkanen E, Perola M, 39. 448 Schunkert H, Sijbrands EJ, et al. Genomic prediction of coronary heart disease. European Heart 449 Journal. 2016;37:3267-3278. doi: 10.1093/eurheartj/ehw450 450 40. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, Yu GZ, Rüeger S, Speidel L, Kim 451 YJ, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse 452 populations for discovery and translation. Nature Genetics. 2022;54:560-572. doi: 453 10.1038/s41588-022-01058-3 454 41. Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan JA, Willems SM, Wu Y, Zhang X, 455 Horikoshi M, et al. The trans-ancestral genomic architecture of glycemic traits. *Nature Genetics*. 456 2021;53:840-860. doi: 10.1038/s41588-021-00852-9 457 42. Chen M-H, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, Trivedi B, Jiang T, Akbari P, Vuckovic D, et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals 458 459 from 5 Global Populations. Cell. 2020;182:1198-1213.e1114. doi: 10.1016/j.cell.2020.06.045 460 43. Lu X, Liu Z, Cui Q, Liu F, Li J, Niu X, Shen C, Hu D, Huang K, Chen J, et al. A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort 461 462 study. European Heart Journal. 2022;43:1702-1711. doi: 463 https://doi.org/10.1093/eurheartj/ehac093 464 44. Graham SE, Clarke SL, Wu K-HH, Kanoni S, Zajac GJM, Ramdas S, Surakka I, Ntalla I, Vedantam S, 465 Winkler TW, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature. 2021;600:675-679. doi: 10.1038/s41586-021-04064-3 466 467 45. Evans DM, Cardon LR. A Comparison of Linkage Disequilibrium Patterns and Estimated 468 Population Recombination Rates across Multiple Populations. The American Journal of Human 469 Genetics. 2005;76:681-687. doi: 10.1086/429274

470	46.	Cavazos TB, Witte JS. Inclusion of variants discovered from diverse populations improves
471		polygenic risk score transferability. HGG Adv. 2021;2:100017. doi:
472		https://doi.org/10.1016/j.xhgg.2020.100017
473	47.	Zhang Y, Qi G, Park J-H, Chatterjee N. Estimation of complex effect-size distributions using
474		summary-level statistics from genome-wide association studies across 32 complex traits. Nature
475		Genetics. 2018;50:1318-1326. doi: 10.1038/s41588-018-0193-x
476	48.	Privé F, Aschard H, Carmi S, Folkersen L, Hoggart C, O'Reilly PF, Vilhjálmsson BJ. Portability of 245
477		polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the
478		same cohort. The American Journal of Human Genetics. 2022;109:12-23. doi:
479		10.1016/i.aihg.2021.11.008
480	49.	Fahed AC, Aragam KG, Hindy G, Chen Y-DI, Chaudhary K, Dobbyn A, Krumholz HM, Sheu WHH.
481		Rich SS. Rotter JI. et al. Transethnic Transferability of a Genome-Wide Polygenic Score for
482		Coronary Artery Disease, Circulation: Genomic and Precision Medicine, 2021:14, doi:
483		10.1161/circgen.120.003092
484	50.	Arnett DK. Blumenthal RS. Albert MA. Buroker AB. Goldberger 7D. Hahn FI. Himmelfarh CD.
485		Khera AV. Llovd-Jones D. McEvov IW. et al. 2019 ACC/AHA Guideline on the Primary Prevention
486		of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart
487		Association Task Force on Clinical Practice Guidelines, <i>Journal of the American College of</i>
488		Cardiology, 2019:74:177-232, doi: https://doi.org/10.1016/i.jacc.2019.03.010
489	51.	Volgman AS. Palanjappan I.S. Aggarwal NT. Gupta M. Khandelwal A. Krishnan AV. Lichtman JH.
490		Mehta LS. Patel HN. Shah KS. et al. Atherosclerotic Cardiovascular Disease in South Asians in the
491		United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the
492		American Heart Association. <i>Circulation</i> . 2018:138:CIR.0000000000. doi:
493		10.1161/cir.000000000000580
494	52.	Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland
495		DT, Levy D, O'Donnell CJ, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular
496		Risk. <i>Circulation</i> . 2014:129:S49-S73. doi: 10.1161/01.cir.0000437741.48606.98
497	53.	Kullo IJ, Jouni H, Olson JE, Montori VM, Bailey KR. Design of a randomized controlled trial of
498		disclosing genomic risk of coronary heart disease: the Myocardial Infarction Genes (MI-GENES)
499		study. BMC Medical Genomics. 2015;8. doi: 10.1186/s12920-015-0122-0
500	54.	The Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium.
501		https://primedconsortium.org/. 2021.
502	55.	Atkinson EG, Maihofer AX, Kanai M, Martin AR, Karczewski KJ, Santoro ML, Ulirsch JC, Kamatani
503		Y, Okada Y, Finucane HK, et al. Tractor uses local ancestry to enable the inclusion of admixed
504		individuals in GWAS and to boost power. <i>Nature Genetics</i> . 2021;53:195-204. doi:
505		10.1038/s41588-020-00766-y
506	56.	Cai M, Xiao J, Zhang S, Wan X, Zhao H, Chen G, Yang C. A unified framework for cross-population
507		trait prediction by leveraging the genetic correlation of polygenic traits. <i>The American Journal of</i>
508		Human Genetics. 2021;108:632-655. doi: 10.1016/j.ajhg.2021.03.002
509	57.	Weissbrod O, Kanai M, Shi H, Gazal S, Peyrot WJ, Khera AV, Okada Y, Matsuda K, Yamanashi Y,
510		Furukawa Y, et al. Leveraging fine-mapping and multipopulation training data to improve cross-
511		population polygenic risk scores. <i>Nature Genetics</i> . 2022;54:450-458. doi: 10.1038/s41588-022-
512		01036-9
513	58.	Amariuta T, Ishigaki K, Sugishita H, Ohta T, Koido M, Dey KK, Matsuda K, Murakami Y, Price AL,
514		Kawakami E, et al. Improving the trans-ancestry portability of polygenic risk scores by prioritizing

# variants in predicted cell-type-specific regulatory elements. *Nature Genetics*. 2020;52:13461354. doi: 10.1038/s41588-020-00740-8

517

518

Ancestry	Age <sup>a</sup>	Cases/Controls	Method	AUC	OR <sup>d</sup> (95% CI <sup>e</sup> )	P-value	OR (95% CI) Top	P-value
	(mean±SD <sup>b</sup> )				per 1 SD		5% vs Rest	
	52.4 ± 15.5	4,970/47,732	PRS <sub>P+T</sub>	0.773	1.65	3.00E-159	2.30	5.71E-55
					(1.59-1.72)		(2.07-2.56)	
EUR			PRS <sub>CSx</sub>	0.774	1.65	5.19E-171	2.48	5.88E-61
					(1.59-1.71)		(2.23-2.77)	
	53.4 ± 14.7	1,359/15,649	PRS <sub>P+T</sub>	0.735	1.16	2.86E-12	1.68	5.51E-08
AED					(1.11-1.21)		(1.39-2.03)	
Агл			PRS <sub>CSx</sub>	0.736	1.20	7.46E-14	1.74	3.03E-07
					(1.15-1.26)		(1.41-2.15)	
	54.8 ± 14.3	314/5,824	PRS <sub>P+T</sub>	0.699	1.38	5.89E-09	2.16	1.02E-04
шіс					(1.24-1.54)		(1.47-3.19)	
ПІЗ			PRS <sub>CSx</sub>	0.706	1.51	7.48E-13	2.57	7.98E-07
					(1.35-1.69)		(1.77-3.73)	
	65.4 ± 12.9	6,321/16,430	PRS <sub>P+T</sub>	0.748	1.56	2.97E-146	2.47	1.24E-39
FAS					(1.50-1.61)		(2.10-2.90)	
LAS			PRS <sub>CSx</sub>	0.762	1.59	2.41E-160	2.34	1.78E-28
					(1.54-1.64)		(2.06-2.66)	
	53.2 ± 8.4	517/8,661	PRS <sub>P+T</sub>	0.786	2.75	9.44E-52	3.95	3.07E-24
SVZ					(2.41-3.14)		(3.03-5.15)	
SAS			PRS <sub>CSx</sub>	0.803	2.67	1.48E-63	4.92	3.90E-34
					(2.38-3.00)		(3.81-6.35)	

**Table 1.** Odds Ratios for incident CHD for multi-ancestry PRS<sub>P+T</sub> and PRS<sub>CSx</sub> in diverse ancestry cohorts.

<sup>a</sup> Age- Age at enrollment

521 <sup>b</sup> SD- Standard Deviation

522 <sup>c</sup>AUC-Area under the Curve

523 <sup>d</sup> OR- Odds Ratio

<sup>e</sup> CI- Confidence Interval

### 525 Figures



526

527 Figure 1. Polygenic Risk Score development using independent MVP cohorts of diverse ancestry.



### 529



represent the GWAS summary statistics used to construct the PRS (green for AFR, purple for EAS, orange for EUR, and grey for the multi-ancestry meta-

- 532 analysis). The Odds Ratios (ORs) per 1 standard deviation (SD) increase with confidence intervals (CIs) in the PRS are represented on the Y-axis and the
- 533 populations on which the PRS is trained are on the X-axis.



534

**Figure 3.** Comparison of a prior PRS (metaGRS) and two new PRS using multi-ancestry summary statistics for the prediction of coronary heart

536 disease (CHD) using the ancestrally diverse training cohort of the MVP. Odds Ratios (ORs) per standard deviation (SD) with confidence intervals

538 performed on the MVP training cohort.

<sup>537 (</sup>CIs) are shown for each genetic ancestry group as determined in the methods as a result of metaGRS, P+T, and PRS-CSx PRS methods being